Fundamental Analysis of SPYRE THERAPEUTICS INC(NASDAQ:SYRE) stock

Fundamental Rating

Taking everything into account, SYRE scores 3 out of 10 in our fundamental rating. SYRE was compared to 566 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SYRE as it has an excellent financial health rating, but there are worries on the profitability. SYRE does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SYRE has reported negative net income.

SYRE had a negative operating cash flow in the past year.

SYRE had negative earnings in each of the past 5 years.

In the past 5 years SYRE always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of SYRE (-42.65%) is comparable to the rest of the industry.

SYRE has a better Return On Equity (-49.68%) than 66.67% of its industry peers.

		Industry Rank	Sector Rank
ROA	-42.65%
ROE	-49.68%
ROIC	N/A

ROA(3y)-92.29%

ROA(5y)-84.19%

ROE(3y)-123.74%

ROE(5y)-111.85%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SYRE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SYRE does not have a ROIC to compare to the WACC, probably because it is not profitable.

SYRE has more shares outstanding than it did 1 year ago.

SYRE has more shares outstanding than it did 5 years ago.

SYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 14.11 indicates that SYRE is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 14.11, SYRE belongs to the top of the industry, outperforming 88.77% of the companies in the same industry.

There is no outstanding debt for SYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	14.11

ROIC/WACCN/A

WACC10.86%

2.3 Liquidity

A Current Ratio of 19.70 indicates that SYRE has no problem at all paying its short term obligations.

SYRE's Current ratio of 19.70 is amongst the best of the industry. SYRE outperforms 94.12% of its industry peers.

A Quick Ratio of 19.70 indicates that SYRE has no problem at all paying its short term obligations.

SYRE has a Quick ratio of 19.70. This is amongst the best in the industry. SYRE outperforms 94.12% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	19.7
Quick Ratio	19.7

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SYRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.29%, which is quite impressive.

Looking at the last year, SYRE shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.

SYRE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -25.61% yearly.

EPS 1Y (TTM)72.29%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%97.93%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y-25.61%

Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, SYRE will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.09% on average per year.

Based on estimates for the next years, SYRE will show a very negative growth in Revenue. The Revenue will decrease by -21.00% on average per year.

EPS Next Y93.8%

EPS Next 2Y39.26%

EPS Next 3Y24.47%

EPS Next 5Y14.09%

Revenue Next Year269.23%

Revenue Next 2Y135.34%

Revenue Next 3Y-25.99%

Revenue Next 5Y-21%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SYRE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year SYRE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

SYRE's earnings are expected to grow with 24.47% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y39.26%

EPS Next 3Y24.47%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SYRE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SPYRE THERAPEUTICS INC

NASDAQ:SYRE (10/29/2024, 11:19:22 AM)

33.445

-0.95 (-2.78%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.70B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-42.65%
ROE	-49.68%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	19.7
Quick Ratio	19.7
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)72.29%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y93.8%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

SPYRE THERAPEUTICS INC (SYRE)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens